Compare Sana Biotechnology Inc (SANA) vs Shell PLC (SHEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Shell PLC — how do they compare? Sana Biotechnology Inc trades at $2.8 (market cap $836.71M), while Shell PLC trades at $100.36 (market cap $284.34B). The key difference: Shell PLC is far larger — about 339.8× Sana Biotechnology Inc's market cap, and Shell PLC pays a 3.12% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Sana Biotechnology Inc for 23 Days and Shell PLC for 90 Days on average.
| SANA | SHEL | |
|---|---|---|
Market Cap | $836.71M | $284.34B |
Volume | 4,507,444 | 9,097,469 |
Sector | Health | Energy |
52-Week High | $5.92 | $100.20 |
52-Week Low | $2.68 | $70.31 |
Typical Hold Time | 23 Days | 90 Days |
Enterprise Value | $749.96M | $326.04B |
Dividend Yield | — | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $2.84, up 4.41% today, while showing bearish technical signals with moving averages indicating selling pressure. The company remains pre-revenue with significant losses (-$244.17M net income in 2025) and negative cash flow from operations. Recent investor conference presentations highlight ongoing development of engineered cell therapies, though earnings have missed expectations in two of the last three quarters.
Despite analyst optimism (82% buy ratings), SANA faces substantial execution risk as a clinical-stage biotech with no current revenue and high cash burn. The stock's outlook depends heavily on clinical trial progress and future funding needs, with current valuation at 5.41x book value despite negative profitability metrics.
Shell (SHEL) trades at $100.18, up 3.44% with strong technical momentum and bullish analyst sentiment. The stock shows robust fundamentals with a P/E of 11.08, ROE of 14.35%, and recent earnings beats. Recent developments include the LNG Canada Phase 2 expansion approval, doubling export capacity, positioning Shell for long-term LNG growth. Cash flow remains healthy despite a temporary net outflow in 2025.
Shell presents a compelling investment case with attractive valuation, strong profitability, and strategic LNG expansion. Risks include revenue volatility from oil prices and execution challenges in major projects. Analyst consensus is bullish with a $102.53 price target, suggesting modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Shell PLC
Shell is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2021, it produced 1.7 million barrels of liquids and 8.7 billion cubic feet of natural gas per day. At year-end 2021, reserves stood at 9.2 billion barrels of oil equivalent, 50% of which consisted of liquids. Its production and reserves are in Europe, Asia, Oceania, Africa, and North and South America. The company operates refineries with capacity of 1.8 mmb/d located in the Americas, Asia, Africa, and Europe and sells 15 mtpa of chemicals. Its largest chemical plants, often integrated with its local refineries, are in Central Europe, China, Singapore, and North America.
Read more on SHEL →
